At a glance
- Originator Novartis
- Class Anti-inflammatories
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 07 Sep 1998 No-Development-Reported for Inflammation in USA (PO)
- 03 Sep 1996 Preclinical development for Inflammation in USA (PO)